Moderna Inc MRNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
153.30quote price arrow down-1.51 (-0.98%)
Volume
727,440
Close
154.81quote price arrow up+6.43 (+4.33%)
Volume
11,986,795
52 week range
19.31 - 189.26

...

Loading . . .

KEY STATS

  • Open157.98
  • Day High159.60
  • Day Low150.88
  • Prev Close148.38
  • 52 Week High189.26
  • 52 Week High Date02/08/21
  • 52 Week Low19.31
  • 52 Week Low Date03/13/20
  • Market Cap61.26B
  • Shares Out395.71M
  • 10 Day Average Volume8.78M
  • Dividend-
  • Dividend Yield-
  • Beta1.5
  • 1 Year % Change491.78

RATIOS/PROFITABILITY

  • EPS (TTM)-1.94
  • P/E (TTM)-79.91
  • Fwd P/E (NTM)15.80
  • EBITDA (MRQ)-739.599M
  • ROE (MRQ)-29.80%
  • Revenue (MRQ)803.40M
  • Gross Margin (MRQ)70.05%
  • Net Margin (MRQ)-92.99%
  • Debt To Equity (MRQ)3.94%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

QUOTE FINDER

Related Video

VIDEO2:4502:45
It's not just coronavirus vaccines that will boost Moderna's share price: Jefferies

Profile

MORE
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...
Noubar Afeyan Ph.D.
Non-Executive Chairman
Stephane Bancel
Chief Executive Officer
Stephen Hoge M.D.
President
David Meline
Chief Financial Officer
Juan Andres
Chief Technology Officer
Lori Henderson J.D.
General Counsel
Address
200 Technology Sq
Cambridge, MA
02139-3578
United States